Evonik enters agreement to supply blueSulfate liquid ammonium sulfate to Interoceanic, a marketer of fertilizer, industrial chemicals; agreement supports Evonik's strategy that includes high-value co-products of its methionine network for crop fertilizers

Sample article from our Chemicals Industry

ESSEN, Germany and KENNESAW, Georgia , July 19, 2022 (press release) –

  • Evonik focuses on core business and markets fertilizer via Interoceanic Corporation
  • Co-product of methionine production serves as a valuable nitrogen fertilizer
  • Contribution to the circularity of macronutrients in agriculture

Evonik has entered into an agreement to supply blueSulfate®, a liquid ammonium sulfate (8-0-0-9) solution from its site in Mobile, Alabama, to Interoceanic Corporation (IOC). This agreement supports Evonik’s strategy to focus on its core business in Animal Nutrition by marketing high-value co-products of its methionine production network for fertilizing crops via IOC. Interoceanic is a marketer of fertilizer and industrial chemicals with a terminal network and multi-modal transportation fleet in North America, linking producers and end users.

This joint effort allows Evonik to bring valuable nitrogen fertilizer to the market that meets the needs of US farmers, contributing to the circularity of macronutrients in agriculture. Evonik manufactures liquid ammonium sulfate (8-0-0-9) solution and a potassium-based fertilizer, AgraLi®, as co-products of its methionine production.

“This agreement was the result of a lot of hard work and forward- thinking by both Evonik and IOC to provide additional products to both American Agriculture and a growing population,” states Doug Mills, Plant Nutrition Business Manager at the Nutrition & Care division of Evonik. “We look forward to a successful relationship with IOC.”

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order chemicals industry coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.